Emerson’s DeltaV Helps Make The COVID-19 Vaccine
CBS Sunday Morning aired challenges pharma companies face for FDA approval to mass produce COVID-19 doses while keeping them cold. Emerson’s DeltaV Electronic Marshalling with CHARMS and cold chain technologies are in focus with a solution. Please watch Emerson's story starting at time 3:40 of the video below. Visit our website for more Life Sciences information.
One of the reasons this new vaccine, based on new mRNA technology, could be brought to market so quickly was in part due to the innovative technology of DeltaV and Electronic Marshalling with CHARMs. Electronic Marshalling and Emerson allowed:
Over 2.4 million CHARMs were deployed with over 97 billion hours of runtime in over 2300 DeltaV systems.
- Vaccine manufacturing facilities to be designed and built before the manufacturing process was fully defined
- Flexibility to make late changes to the process for modifications or testing
- Designed to meet regulatory compliance and validation requirements
- Local expertise to address issues and make sure all questions were resolved quickly
- Syncade software capability used to drive SPEED and FLEXIBILITY needed for Life Sciences Pipeline acceleration
Over 2.4 million CHARMs were deployed with over 97 billion hours of runtime in over 2300 DeltaV systems.